All storiesMetabolic health

Aspirin rarely used for colorectal cancer prevention

Research suggests low-dose aspirin may reduce colorectal cancer risk in people with Lynch syndrome, but its use remains uncommon due to potential side effects.

NeoMD Editors · 2026-10-11

For information, not personal medical advice. Discuss treatment decisions with a qualified clinician.

The quick read

Key takeaways

A new study suggests a low daily aspirin dose (100 mg) may offer similar colorectal cancer prevention benefits for Lynch syndrome patients as a higher 600 mg dose.
Lower aspirin doses may reduce the risk of bleeding complications, a common side effect linked to higher doses in cancer prevention trials.
The evidence applies specifically to Lynch syndrome patients, and further research is needed to determine optimal dosing and long-term safety.

Editorial illustration for Aspirin rarely used for colorectal cancer prevention — AI-generated editorial illustration.

What the Research Found

People with Lynch syndrome have a hereditary predisposition that greatly increases their risk of colorectal and other cancers. Earlier studies, such as the CAPP2 trial, showed that a high daily dose of aspirin (600 mg) could significantly lower the long-term risk of colorectal cancer in this group.

A newly published international study called CaPP3, reported in The Lancet Gastroenterology & Hepatology journal, now suggests that a much lower daily dose of 100 mg aspirin may provide a similar protective effect. This lower dose may also reduce side effects, especially bleeding complications, which have been a concern with higher doses.

Supporting editorial illustration for Aspirin rarely used for colorectal cancer prevention — AI-generated editorial illustration.

Laboratory and Human Evidence

The CAPP2 and CaPP3 studies are based on clinical trials involving humans with Lynch syndrome. These trials observed long-term outcomes including cancer incidence and side effects. The reduced side effects reported with the lower aspirin dose relate mainly to fewer bleeding events, a common risk with aspirin use.

Limitations and Considerations

The studies focus specifically on individuals with Lynch syndrome, a relatively rare hereditary condition, so these findings may not apply to the general population.
The exact balance between cancer prevention benefits and the risks of aspirin side effects requires careful evaluation in each patient.
Further research is needed to confirm optimal dosing and to assess long-term safety.

Implications

These findings may encourage clinicians and patients to consider low-dose aspirin as a preventive strategy against colorectal cancer in Lynch syndrome carriers. However, the decision to use aspirin should be personalized, weighing potential benefits against risks. The fact that aspirin use remains uncommon likely reflects uncertainties about side effects and the need for medical guidance.

Source: Medical Xpress